Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome

被引:18
作者
Adamzik, Michael [1 ,2 ]
Frey, Ulrich H. [1 ,2 ]
Riemann, Kathrin [2 ]
Sixt, Stephan [1 ]
Lehmann, Nils [3 ]
Siffert, Winfried [2 ]
Peters, Juergen [1 ]
机构
[1] Univ Klinikum Essen, Univ Duisburg Essen, Klin Anasthesiol & Intens Med, Essen, Germany
[2] Univ Klinikum Essen, Univ Duisburg Essen, Inst Pharmakogenet, Essen, Germany
[3] Univ Klinikum Essen, Univ Duisburg Essen, Inst Med Informat Biometrie & Epidemiol, Essen, Germany
关键词
acute respiratory distress syndrome; protein C; thrombin; factor V Leiden;
D O I
10.1097/CCM.0b013e318174373d
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Activation of coagulation and inflammation are parts of the innate host response to infection that may contribute to organ dysfunction and death when control of these systems is compromised. Thus, functional single nucleotide polymorphisms within candidate genes of the inflammation and coagulation cascade are possible factors which may influence severity and/or mortality in acute respiratory distress syndrome. The aim of this study was to investigate whether the factor V Leiden mutation (Arg506Gln) is associated with altered severity and/or mortality in acute respiratory distress syndrome. Design: Retrospective cohort, genetic association study. Setting. Tertiary care intensive care unit. Patients., Adults (white Germans) with acute respiratory distress syndrome (n = 106). Interventions: Genotyping for the factor V Leiden mutation. Measurements, and Main Results: Using Kaplan-Meier estimates to compare outcome, 30-day survival was significantly associated with the factor V Leiden mutation (p =.049). Thirty-day survival rates were 100% for Arg/Gln (n = 7) genotypes but only 58% for Arg/Arg (n = 99) genotypes, respectively. Conclusion: We show for the first time that a heterozygous factor V Leiden genotype is associated with improved 30-day survival in patients with acute respiratory distress syndrome.
引用
收藏
页码:1776 / 1779
页数:4
相关论文
共 31 条
[11]  
ESMON CT, 1989, J BIOL CHEM, V264, P4743
[12]   PROTEIN-C AND THE ENDOTHELIUM [J].
ESMON, NL ;
ESMON, CT .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1988, 14 (02) :210-215
[13]  
Espana F., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P119, DOI 10.2174/1568016053544336
[14]   Serial evaluation of the SOFA score to predict outcome in critically ill patients [J].
Ferreira, FL ;
Bota, DP ;
Bross, A ;
Mélot, C ;
Vincent, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (14) :1754-1758
[15]   The proinflammatory cytokine response to coagulation and endotoxin in whole blood [J].
Johnson, K ;
Aarden, L ;
Choi, Y ;
DeGroot, E ;
Creasey, A .
BLOOD, 1996, 87 (12) :5051-5060
[16]   Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia [J].
Kerlin, BA ;
Yan, SB ;
Isermann, BH ;
Brandt, JT ;
Sood, R ;
Basson, BR ;
Joyce, DE ;
Weiler, H ;
Dhainaut, JF .
BLOOD, 2003, 102 (09) :3085-3092
[17]   Effect of the Factor V Leiden mutation on the severity of meningococcal disease [J].
Kondaveeti, S ;
Hibberd, ML ;
Booy, R ;
Nadel, S ;
Levin, M .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (10) :893-896
[18]  
LE GJ, 1993, JAMA-J AM MED ASSOC, V270, P2957
[19]   Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A) [J].
Longstreth, WT ;
Rosendaal, FR ;
Siscovick, DS ;
Vos, HL ;
Schwartz, SM ;
Psaty, BM ;
Raghunathan, TE ;
Koepsell, TD ;
Reitsma, PH .
STROKE, 1998, 29 (03) :577-580
[20]   Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients [J].
Menges, T ;
Hermans, PWM ;
Little, SG ;
Langefeld, T ;
Böning, O ;
Engel, J ;
Sluijter, M ;
de Groot, R ;
Hempelmann, G .
LANCET, 2001, 357 (9262) :1096-1097